ANTEOTECH LTD competitors & alternatives

Similar pharmaceuticals, biotechnology & life sciences company

Headquartered in Ringwood, Australia, and established in 2011, Trajan Group Holdings Limited is a global enterprise focused on designing, manufacturing, marketing, and distributing a diverse range of analytical and life science instruments and associated products. Its extensive operations cover Australia, New Zealand, Malaysia, Japan, the United States, Europe, the Middle East, Africa, and India. The company's activities are organized into two main divisions: Analytical Products and Life Science Solutions. The Analytical Products segment provides essential components such as syringes, GC consumables, septa, caps, liners, gas filters, and tubing. It also supplies pathology and sampling equipment, along with automated systems tailored for examining biological, food, and environmental samples. Complementing this, Trajan delivers nutrition testing solutions for various clients, including pathology laboratories, research and clinical trial initiatives, personalized nutrition programs, corporate wellness strategies, and health insurance providers. The company's offerings further extend to automation workflow solutions, micro-sampling devices, and comprehensive data analysis services.

Anbio BiotechnologyNNNN · BiotechFrankfurt am Main, Germany

66% matchPublic

Biotech

Anbio Biotechnology, established in 2021 and based in Frankfurt am Main, Germany, operates as a global supplier of in vitro diagnostics (IVD) products. The company's international footprint covers regions such as the European Union, Asia Pacific, North America, South America, and Africa. Their product range features various diagnostic solutions, including rapid antigen tests for SARS-CoV-2 (both individual and combined with influenza A/B). Anbio also develops and manufactures products leveraging advanced technologies like lateral flow immunoassay, fluorescence immunoassay, loop-mediated isothermal amplification (LAMP), chemiluminescence immunoassay (CLIA), and reverse-transcription polymerase chain reaction (RT-PCR). These offerings cater to a wide array of markets, including over-the-counter sales, point-of-care testing, and traditional laboratory settings.

APTAMER GROUP PLCAPTA · BiotechYork, United Kingdom

64% matchPublic

Biotech

Aptamer Group plc, an international company headquartered in York, United Kingdom, specializes in providing advanced binders for applications spanning research, diagnostics, and therapeutics. Their innovative binder technology is engineered to resolve challenges often associated with traditional molecular tools, such as antibodies, offering crucial solutions to bioprocessing, diagnostic, and pharmaceutical scientists. Established in 2014, the company primarily serves pharmaceutical corporations, diagnostic development firms, and various research institutes.

Getein Biotech, Inc603387 · BiotechNanjing, China

63% matchPublic

Biotech

Getein Biotech, Inc. is an enterprise primarily focused on the research, development, manufacturing, and global distribution of in vitro diagnostic (IVD) solutions. Founded in 2002 and based in Nanjing, China, the company offers a comprehensive array of diagnostic products. This includes a variety of diagnostic reagents, advanced analytical instruments, and crucial calibrators. Getein also supplies foundational raw materials for reagents, such as monoclonal and polyclonal antibodies, antigens, antiserum, and microspheres. Its extensive product line caters to diverse medical fields, encompassing diagnostics for cardiac markers, inflammatory conditions, renal function, blood coagulation, thyroid disorders, fertility assessments, diabetes care, and thrombus detection. These offerings broadly serve applications in cardiovascular, inflammatory, diabetes, reproductive, renal, hepatic, and other key health areas.

Biotech

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.

Microbix Biosystems Inc.BiotechMississauga, Canada

61% match

Biotech

Microbix Biosystems Inc. is a life science enterprise dedicated to advancing human health globally, including markets across North America and Europe. Established in 1988 and headquartered in Mississauga, Canada, the company specializes in developing and marketing unique biological and technological products. A significant part of its business involves producing essential biological reagents for the diagnostic industry. This encompasses antigens vital for immunoassays, alongside its distinctive Quality Assessment and Proficiency (QAP) products. These QAPs are instrumental for clinical laboratories, providing support for proficiency testing, the development and validation of diagnostic assays, and optimizing routine lab operations. Furthermore, Microbix applies its deep biological knowledge and infrastructure to create additional proprietary offerings. Among these are DxTM, a viral transport medium crucial for stabilizing patient specimens prior to laboratory analysis, and Kinlytic Urokinase, a biopharmaceutical thrombolytic drug employed to treat blood clots. The company channels its QAP sales to accreditation organizations, diagnostic companies, and clinical laboratories via an extensive network of regional distributors.

PROTEOMICS INTERNATIONAL LABORATORIES LTDPIQ · Pharmaceuticals, Biotechnology & Life SciencesNedlands, Australia

63% matchPublic

Similar pharmaceuticals, biotechnology & life sciences company

Proteomics International Laboratories Ltd operates as a medical technology company with a focus on the area of proteomics in Australia, New Zealand, the United States, Europe, India, and Southeast Asia. It provides PromarkerD, a blood test to predict diabetic kidney disease (DKD). The company’s products under development include PromarkerEndo, which has completed clinical validation phase for endometriosis diagnosis; PromarkerEso, which has completed clinical validation trials for esophageal cancer diagnosis; and OxiDx (2-tag), which has completed clinical validation phase for oxidative stress treatment. It is also developing diagnostic tests for that includes DKD - T1D, that is under clinical phase for type 1 diabetes, diabetic retinopathy, and diabetic neuropathy; Asthma and COPD, which has completed proof-of-concept study trials for asthma and chronic obstructive pulmonary disease; Plant Dieback, that is under development phase for phytophthora dieback; Diabetic Retinopathy, which has completed discovery phase for sight-threatening retinopathy; and Diabetic Neuropathy, that is under research phase to investigate predictive biomarkers for diabetic neuropathy. The company also offers analytical services, such as specialist contract research focusing on biomarker discovery, biosimilars quality control, and pharmacokinetic testing for clinical trials. It has strategic collaboration with Harry Perkins Institute of Medical Research, Bioplatforms Australia, The University of Western Australia, Australian Research Council Training Centre, and the Australian Centre. Proteomics International Laboratories Ltd was founded in 2001 and is based in Perth, Australia.

Similar pharmaceuticals, biotechnology & life sciences company

Cleo Diagnostics Ltd is a public pharmaceuticals, biotechnology, and life sciences company based in Australia, traded under the ticker COV.

Pharmaceuticals

Telix Pharmaceuticals is a commercial-stage biopharmaceutical company headquartered in Melbourne, Australia, focused on the development of diagnostic and therapeutic radiopharmaceuticals.

radiopharma rival LantheusBiotechnology & Pharmaceuticals

61% match

Biotechnology & Pharmaceuticals

Lantheus is a radiopharmaceutical-focused company that develops diagnostic and therapeutic products, with a focus on oncology, neurology, and cardiology. The company serves patients and healthcare providers by delivering life-changing science to improve medical outcomes.

GENEDRIVE PLCGDR · BiotechManchester, United Kingdom

63% matchPublic

Biotech

Genedrive Plc, a molecular diagnostics firm established in Manchester, UK, in 2000 (and known as Epistem Holdings Plc until its name change in July 2016), focuses on developing and commercializing innovative point-of-care diagnostic platforms. These solutions cater to a range of applications, including the identification of infectious diseases, genetic profiling, and pathogen detection. At the core of their offerings is the proprietary Genedrive system, a compact polymerase chain reaction (PCR) technology. This advanced platform enables the rapid amplification and detection of nucleic acids from diverse biological samples, such as plasma, sputum, and buccal swabs. The Genedrive platform features several key diagnostic products: the Genedrive HCV ID Kit for qualitative Hepatitis C virus detection; the Genedrive BioPlex, designed for the quick identification of military biothreats from pathogens; and the Genedrive MT-RNR1-ID Kit, a rapid genetic test vital for emergency neonatal care. Complementing these is the Genedrive Connect app, an Android-based mobile application that streamlines data management and facilitates results transmission. Genedrive Plc serves the biotechnology and pharmaceutical sectors globally, with its reach extending throughout the United Kingdom, Europe, the United States, and other international regions. The company has also partnered with Beckman Coulter Life Sciences to automate laboratory PCR testing procedures for COVID-19.

Exagen Inc.XGN · BiotechnologyVista, United States

63% matchPublic

Biotechnology

Exagen Inc. develops and commercializes diagnostic testing solutions, leveraging its proprietary cell-bound complement activation products (CB-CAPs) technology under the AVISE brand throughout the United States. The company's mission is to equip rheumatologists with advanced tools for the precise diagnosis, prognosis, and ongoing management of autoimmune and related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its flagship product, AVISE CTD, aids in distinguishing between various connective tissue diseases (CTDs) and other conditions with overlapping symptoms in symptomatic patients. The company's product portfolio includes AVISE Lupus, which assesses complement system activation by measuring B-cell C4d and erythrocyte-bound C4d in blood. AVISE APS offers a comprehensive panel of autoantibody tests for the diagnosis and management of Antiphospholipid Syndrome (APS). For SLE patients, AVISE SLE Prognostic provides an autoantibody panel to evaluate the potential for kidney, brain, and cardiovascular complications. Additionally, AVISE Vasculitis AAV utilizes a testing panel of individual analytes to assist physicians in the assessment and monitoring of anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis, while AVISE Anti-CarP helps identify RA patients prone to severe disease, and AVISE PC4d measures platelet-bound C4d. Further offerings include AVISE SLE Monitor, a biomarker blood test; AVISE MTX, a patented and validated blood test; and AVISE HCQ, designed to monitor hydroxychloroquine levels. Exagen also holds a research collaboration and license agreement with Allegheny Health Network (AHN) Research Institute to advance the development of novel patented biomarkers. Incorporated in 2002, the company was formerly known as Exagen Diagnostics, Inc. before rebranding to Exagen Inc. in January 2019. Its headquarters are located in Vista, California.